NEW YORK, March 15 – DeCode Genetics said Thursday its full-year 2000 revenue rose 30 percent to $21.5 million, compared with $16.6 million in 1999, due primarily to higher milestone payments stemming from the company’s research collaboration with Roche.

Of the $21.5 million, $10.1 million in revenues was recorded in the fourth quarter. However, DeCode did not report other figures on a quarterly basis.

For the year, DeCode recorded a 47 percent increase in total operating expenses to $61.1 million, as research and development and general and administrative costs rose.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.